NSCLC – Page 2 – Medxy AI

Prolonged Survival Transforms Leptomeningeal Metastasis in NSCLC: Contemporary Multicenter Cohort Shows TKIs and ICIs Improve Outcomes

By MedXY 11/12/2025

An international cohort of 2,052 NSCLC patients with leptomeningeal disease shows rising prevalence and improved survival in the modern treatment era. CNS‑penetrant tyrosine kinase inhibitors and immune checkpoint inhibitors are key drivers of delayed onset and longer leptomeningeal survival.

news Oncology Respiratory

Efficacy of Afatinib Combined with Chemotherapy in Post-Osimertinib EGFR-Mutated NSCLC: Insights from the NEJ025B Study

By MedXY 10/25/2025

This phase II study evaluates the effectiveness and safety of afatinib with platinum-based chemotherapy in NSCLC patients resistant to first-line osimertinib, highlighting promising outcomes and manageable toxicity.

Oncology Respiratory

Enhanced Survival in EGFR-Mutated NSCLC: Impact of Amivantamab-Lazertinib vs. Osimertinib

By MedXY 10/25/2025

This article reviews a phase 3 trial comparing overall survival of amivantamab-lazertinib versus osimertinib in untreated EGFR-mutated advanced NSCLC, highlighting efficacy, safety, and clinical implications.

news Oncology Respiratory

Enhanced Survival in EGFR-Mutated NSCLC: The Impact of Combining Osimertinib with Chemotherapy

By MedXY 10/25/2025

This article reviews the latest evidence demonstrating improved overall survival with osimertinib combined with chemotherapy in first-line treatment of EGFR-mutated advanced non-small-cell lung cancer.

Oncology

Cutting-Edge Treatment for EGFR-Mutated NSCLC: Sacituzumab Tirumotecan Shows Promising Survival Benefits

By MedXY 10/25/2025

A phase 3 trial demonstrates that sacituzumab tirumotecan significantly improves progression-free and overall survival in EGFR-mutated advanced NSCLC resistant to TKI therapy.

Oncology Respiratory

Advancing First-Line Treatment in Metastatic NSCLC: The Promise of Retifanlimab Combined with Chemotherapy

By MedXY 10/17/2025

This article reviews the phase 3 POD1UM-304 trial demonstrating that adding retifanlimab to platinum-based chemotherapy improves overall survival in first-line metastatic NSCLC, highlighting its potential as a new standard of care.

Clinical Updates news Oncology

Reevaluating the Role of Adjuvant Immunotherapy After Neoadjuvant Chemoimmunotherapy in Resectable Stage III NSCLC: Results from a Two-Center Real-World Study

By MedXY 09/25/2025

This study suggests adjuvant immunotherapy may not enhance survival after neoadjuvant chemoimmunotherapy and surgery in stage III NSCLC, with three cycles of neoadjuvant immunotherapy appearing optimal.

Clinical Updates news Oncology Specialties

Impact of Antibiotics, Steroids, and PPIs on Survival in Advanced NSCLC Patients Treated with First-Line Pembrolizumab

By MedXY 09/24/2025

This nationwide cohort study reveals that certain antibiotics, higher-dose steroids, and proton pump inhibitors are associated with reduced overall survival in advanced NSCLC patients receiving first-line pembrolizumab, underscoring the importance of careful comedication monitoring during immunotherapy.

Clinical Updates news Oncology

Targeting the MEK/RTK Axis: A Promising Combination Therapy for KRAS-Mutant Non-Small Cell Lung Cancer

By MedXY 09/19/2025

Combining MEK inhibitor trametinib with pan-RTK inhibitor anlotinib shows high efficacy and manageable toxicity in treating advanced non-G12C KRAS-mutant NSCLC, overcoming adaptive resistance and offering improved clinical outcomes.

Clinical Updates Oncology Specialties

Updated Phase III HARMONi Trial Data Reveal Enhanced Survival Benefits of Ivonescimab in NSCLC

By MedXY 09/07/2025

Recent updates from the global Phase III HARMONi study demonstrate envafolimab’s significant improvement in overall and progression-free survival in NSCLC, with consistent benefits across diverse populations, reinforcing its emerging role in lung cancer therapy.

Oncology Specialties

High-Dose Vitamin C Induces Pyroptosis in LKB1-Mutant Lung Cancer and Enhances Immunotherapy Response

By MedXY 08/23/2025

New research reveals that high-dose vitamin C selectively kills LKB1-mutant NSCLC cells by inducing pyroptosis, reversing immunotherapy resistance and improving T cell infiltration through GLUT1-mediated uptake and ROS-mediated cell death.

Clinical Updates news Oncology Specialties

Comparative Efficacy and Safety of Limertinib versus Gefitinib in First-Line Treatment of EGFR-Mutated Advanced NSCLC: A Phase 3 Randomized Trial

By MedXY 08/02/2025

Limertinib demonstrates superior progression-free survival and a comparable safety profile to gefitinib, supporting its use as a first-line therapy in EGFR-mutated locally advanced or metastatic NSCLC.